Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Total Debt (2016 - 2025)

Lifecore Biomedical, Inc. \De\ (LFCR) has 15 years of Total Debt data on record, last reported at $5.8 million in Q2 2025.

  • For Q2 2025, Total Debt fell 75.5% year-over-year to $5.8 million; the TTM value through May 2025 reached $5.8 million, down 75.5%, while the annual FY2025 figure was $5.8 million, 75.5% down from the prior year.
  • Total Debt reached $5.8 million in Q2 2025 per LFCR's latest filing, down from $8.3 million in the prior quarter.
  • Across five years, Total Debt topped out at $193.9 million in Q2 2021 and bottomed at $5.8 million in Q2 2025.
  • Average Total Debt over 5 years is $72.9 million, with a median of $44.0 million recorded in 2022.
  • Peak YoY movement for Total Debt: surged 112.09% in 2023, then plummeted 90.01% in 2024.
  • A 5-year view of Total Debt shows it stood at $166.2 million in 2021, then crashed by 71.12% to $48.0 million in 2022, then surged by 93.45% to $92.9 million in 2023, then tumbled by 90.01% to $9.3 million in 2024, then plummeted by 37.44% to $5.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Debt were $5.8 million in Q2 2025, $8.3 million in Q1 2025, and $9.3 million in Q4 2024.